Preferable stimulation of PON1 arylesterase activity by phosphatidylcholines with unsaturated acyl chains or oxidized acyl chains at sn-2 position

Biochimica et Biophysica Acta - Biomembranes

Volumn 1758, Issue 4, 2006, Pages 499-508

  Nguyen, Su Duy ^a   Sok, Dai Eun ^a  

^a Chungnam National University   (South Korea)

Author keywords

Acyl chain; Arylesterase; Oxidized; Paraoxonase; Phospholipid; PON1; Preferable stimulation; Unsaturation

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLSERINE;

ARTICLE; DNA DAMAGE; ENZYME ACTIVITY; HUMAN; LIPID BILAYER; MICELLIZATION; PRIORITY JOURNAL;

ACYLATION; ARYLDIALKYLPHOSPHATASE; ENZYME ACTIVATION; HUMANS; KINETICS; LIPOPROTEINS; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS;

EID: 33646861598     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.03.022     Document Type: Article

References (62)

1. La Du B.N. Structural and functional diversity of paraoxonase. Nat. Med. 2 (1996) 1186-1187
2. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., and Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 (1995) 2488-2496
3. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., and Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7 (1996) 69-76
4. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275 (2000) 3957-3962
5. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14 (1996) 334-336
6. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
7. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
8. Watson A.D., Navab M., Hama S.Y., Sevanian A., Prescott S.M., Stafforini D.M., McIntyre T.M., Du B.N., Fogelman A.M., and Berliner J.A. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95 (1995) 774-782
9. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., and Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34 (2003) 774-784
10. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., and Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
11. Rozenberg O., Shih D.M., and Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181 (2005) 9-18
12. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
13. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004) 1304-1316
14. Mackness B., Hine D., Liu Y., Mastorikou M., and Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318 (2004) 680-683
15. Rosenblat M., Vaya J., Shih D., and Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179 (2005) 69-77
16. Bergmeier C., Siekmeier R., and Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 50 (2004) 2309-2315
17. M. Rosenblat, R. Karry, M. Aviram, Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes, Atherosclerosis (in press).
18. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Datta G., Garber D., and Fogelman A.M. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr. Opin. Lipidol. 15 (2004) 645-649
19. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., and Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
20. Paragh G., Balla P., Katona E., Seres I., Egerhazi A., and Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 252 (2002) 63-67
21. James R.W., Leviev I., and Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101 (2000) 2252-2257
22. Seres I., Paragh G., Deschene E., Fulop Jr. T., and Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp. Gerontol. 39 (2004) 59-66
23. Nguyen S.D., and Sok D.E. Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids. J. Lipid Res. 45 (2004) 2211-2220
24. L. Jaouad, C. de Guise, H. Berrougui, M. Cloutier, M. Isabelle, T. Fulop, H. Payette, A. Khalil, Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups, Atherosclerosis (in press).
25. La Du B.N., Adkins S., Kuo C.L., and Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact. 87 (1993) 25-34
26. Kuo C.L., and La Du B.N. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23 (1995) 935-944
27. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., and La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26 (1999) 892-904
28. Gennis R.B. Biomembranes: Molecular Structure and Function (1989), Springer-Verlag, New York 1-84
29. Epand R.M. Lipid polymorphism and protein-lipid interactions. Biochim. Biophys. Acta 1376 (1998) 353-368
30. Nguyen S.D., and Sok D.E. Beneficial effect of oleoylated lipids on paraoxonase1: protection against oxidative inactivation and stabilization. Biochem. J. 375 (2003) 275-285
31. Eckerson H.W., Wyle C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
32. Redgrave T.G., Roberts D.C., and West C.E. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65 (1975) 42-49
33. Chatterjee S., and Banerjee D.K. Preparation, isolation, and characterization of liposomes containing natural and synthetic lipids. Methods Mol. Biol. 199 (2002) 3-16
34. Litman B.J. Lipid model membranes. Characterization of mixed phospholipid vesicles. Biochemistry 12 (1973) 2545-2554
35. Megli F.M., Russo L., and Sabatini K. Oxidized phospholipids induce phase separation in lipid vesicles. FEBS Lett. 579 (2005) 4577-4584
36. Josse D., Xie W., Renault F., Rochu D., Schopfer L.M., Masson P., and Lockridge O. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 38 (1999) 2816-2825
37. Steel R.G.D., and Torrie J.H. Analysis of variance I: The one-way classification. Principles and Procedures of Statistics (1960), McGraw-Hill, New York 99-132
38. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr. Opin. Lipidol. 14 (2003) 421-430
39. Walker J.M., and Sando J.J. Activation of protein kinase C by short chain phosphatidylcholines. J. Biol. Chem. 263 (1988) 4537-4540
40. Powl A.M., East J.M., and Lee A.G. Lipid-protein interactions studied by introduction of a tryptophan residue: the mechanosensitive channel MscL. Biochemistry 42 (2003) 14306-14317
41. Slater S.J., Kelly M.B., Taddeo F.J., Ho C., Rubin E., and Stubbs C.D. The modulation of protein kinase C activity by membrane lipid bilayer structure. J. Biol. Chem. 269 (1994) 4866-4871
42. Chicano J.J., Ortiz A., Teruel J.A., and Aranda F.J. Organotin compounds alter the physical organization of phosphatidylcholine membranes. Biochim. Biophys. Acta 1510 (2001) 330-341
43. Litman B.J., Lewis E.N., and Levin I.W. Packing characteristics of highly unsaturated bilayer lipids: raman spectroscopic studies of multilamellar phosphatidylcholine dispersions. Biochemistry 30 (1991) 313-319
44. Niebylski C.D., and Salem Jr. N. A calorimetric investigation of a series of mixed-chain polyunsaturated phosphatidylcholines: effect of sn-2 chain length and degree of unsaturation. Biophys. J. 67 (1994) 2387-2393
45. Drobnies A.E., van Der Ende B., Thewalt J.L., and Cornell R.B. CTP: phosphocholine cytidylyltransferase activation by oxidized phosphatidylcholines correlates with a decrease in lipid order: a 2H NMR analysis. Biochemistry 38 (1999) 15606-15614
46. Haque M.E., and Lentz B.R. Roles of curvature and hydrophobic interstice energy in fusion: studies of lipid perturbant effects. Biochemistry 43 (2004) 3507-3517
47. Heerklotz H., and Epand R.M. The enthalpy of acyl chain packing and the apparent water-accessible apolar surface area of phospholipids. Biophys. J. 80 (2001) 271-279
48. Huang C., Mason J.T., Stephenson F.A., and Levin I.W. Polymorphic phase behavior of platelet-activating factor. Biophys. J. 49 (1986) 587-595
49. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., and Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 (2004) 412-419
50. Riske K.A., Fernandez R.M., Nascimento O.R., Bales B.L., and Lamy-Freund M.T. DMPG gel-fluid thermal transition monitored by a phospholipid labeled at the acyl chain end. Chem. Phys. Lipids 124 (2003) 69-80
51. van Dijck P.W., de Kruijff B., Verkleij A.J., van Deenen L.L., and de Gier J. Comparative studies on the effects of pH and Ca2+ on bilayers of various negatively charged phospholipids and their mixtures with phosphatidylcholine. Biochim. Biophys. Acta 512 (1978) 84-96
52. Giorgione J.R., Kraayenhof R., and Ep R.M. Interfacial membrane properties modulate protein kinase C activation: role of the position of acyl chain unsaturation. Biochemistry 37 (1998) 10956-10960
53. Davies S.M., Epand R.M., Kraayenhof R., and Cornell R.B. Regulation of CTP: phosphocholine cytidylyltransferase activity by the physical properties of lipid membranes: an important role for stored curvature strain energy. Biochemistry 40 (2001) 10522-10531
54. Fuller N., Benatti C.R., and Rand R.P. Curvature and bending constants for phosphatidylserine-containing membranes. Biophys. J. 85 (2003) 1667-1674
55. Senisterra G., and Epand R.M. Role of membrane defects in the regulation of the activity of protein kinase C. Arch. Biochem. Biophys. 300 (1993) 378-383
56. Kachar B., Fuller N., and Rand R.P. Morphological responses to calcium-induced interaction of phosphatidylserine-containing vesicles. Biophys. J. 50 (1986) 779-788
57. Fuhrman B., Volkova N., and Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 180 (2005) 55-61
58. Gaidukov L., and Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44 (2005) 11843-11854
59. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., Yu N., Ansell B.J., Datta G., Garber D.W., and Fogelman A.M. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1325-1331
60. Ahmed Z., Babaei S., Maguire G.F., Draganov D., Kuksis A., La Du B.N., and Connelly P.W. Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovasc. Res. 57 (2003) 225-231
61. Benitez S., Sanchez-Quesada J.L., Ribas V., Jorba O., Blanco-Vaca F., Gonzalez-Sastre F., and Ordonez-Llanos J. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 108 (2003) 92-96
62. Ishimoto Y., Yamada K., Yamamoto S., Ono T., Notoya M., and Hanasaki K. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim. Biophys. Acta 1642 (2003) 129-138